TNF and inflammatory bowel disease: In IBD, CL of anti-TNFα is influenced by several factors, including the presence of anti-drug antibodies, intrinsic metabolism and recirculation of the drug, inflammatory burden, protein loss through inflamed mucosa, and other patient characteristics [27,28].